Sevoflurane in Paediatric Anaesthesia

Authors:

Abstract
Sevoflurane is an ether inhalation anaesthetic agent with low pungency, a non-irritant odour and a low blood: gas partition coefficient. It can be rapidly and conveniently administered without discomfort, and its low solubility facilitates precise control over the depth of anaesthesia and a rapid and smooth induction of, and emergence from, general anaesthesia. As an induction and maintenance agent for ambulatory and nonambulatory surgery in children, sevoflurane provides more rapid induction of, and emergence from, anaesthesia than halothane, and has similar or better patient acceptability. Time to discharge from the recovery area is usually at least as fast with sevoflurane as with halothane. While rapid emergence from sevoflurane lessens the time spent under anaesthesia, postoperative pain may be more intense and occur earlier than during more gradual emergence. Sevoflurane has been used successfully as an induction agent for tracheal intubation and laryngeal mask airway (LMA) insertion: time to LMA insertion is faster with sevoflurane than halothane, but the 2 drugs provide similar conditions for tracheal intubation. The pattern and incidence of induction and emergence events such as cough, laryngospasm and agitation/excitement is similar with sevoflurane and halothane; however, sevoflurane may cause less postoperative nausea and vomiting. At present, differences have not been consistently shown between the 2 drugs in their propensity to cause postoperative excitement or agitation. Compared with halothane, sevoflurane has low potential for arrhythmogenicity. Clinical experience does not substantiate concerns over the potential nephrotoxicity of the sevoflurane byproducts pentafluoroisopropenyl fluoromethyl ether (‘Compound A’) and plasma F− ions; no renal impairment has been documented in children receiving sevoflurane in clinical trials. The potential for sevoflurane hepatotoxicity also appears negligible. There are few trials comparing sevoflurane with agents other than halothane in paediatric anaesthesia. As well, pharmacoeconomic analyses are scarce and incompletely published; further studies are needed to determine whether shortened times to emergence will translate into cost savings. Conclusion: Sevoflurane is a preferred anaesthetic agent for induction and maintenance of paediatric anaesthesia because of its rapid induction and recovery characteristics, lack of pungency and agreeable odour, and acceptable cardiovascular profile. Although the issue of postoperative excitement requires clarification, sevoflurane anaesthesia can be considered a rational choice for ambulatory and nonambulatory surgery in children. Sevoflurane is a nonpungent ether inhalation anaesthetic agent. The anaesthetic potency of sevoflurane is age-dependent, sevoflurane being less potent in children than in adults. Concomitant use with nitrous oxide (N2O), clonidine, or opioids increases the potency of sevoflurane. The effects of sevoflurane on various body systems generally parallel those produced by other inhalation anaesthetics (most systems are depressed in a dose-related manner). The cerebrovasodilatory effect of sevoflurane was similar to that of halothane in 18 children. Sevoflurane also has cardiovascular depressant effects that are similar in type to those of desflurane and isoflurane in patients and healthy volunteers, although comparisons with halothane in children give variable results. Administration with N2O 60%, spontaneous ventilation or prolonged exposure to sevoflurane attenuate cardiovascular depression and myocardial contractility. Statistically significant increases in heart rate occur in infants and children aged ≤12 years during or soon after induction of anaesthesia with sevoflurane (see also Tolerability summary). Blood pressure is decreased in this population but to a lesser extent than with desflurane, a similar extent to that with isoflurane and generally to a similar or significantly lower extent versus halothane. Sevoflurane, in common with other inhalation anaesthetic agents, causes dose-dependent ventilatory depression which can lead to a decrease in blood pH and to apnoea. Sevoflurane caused greater respiratory depression or changes than halothane at 1 minimum alveolar concentration (MAC) in 30 infants aged 6 to 24 months. Comparison of sevoflurane and isoflurane (both at 1 MAC) in 40 children showed the 2 agents to produce a similar extent and pattern of respiratory depression. Sevoflurane has the advantage over several other inhalation anaesthetic agents, including desflurane, isoflurane and enflurane, of causing negligible airway irritation. Sevoflurane is degraded by CO2 absorbents (used in the anaesthesia circuit) to pentafluoroisopropenyl fluoromethyl ether (PIFE; ‘Compound A’), which is nephrotoxic in rats but has not been shown to cause clinically significant renal injury in patients undergoing anaesthesia. Many studies conducted in adults receiving sevoflurane anaesthesia have detected laboratory markers of renal injury but, overall, sevoflurane does not appear to be associated with a higher risk of renal toxicity than isoflurane, enflurane or propofol, even when sevoflurane is administered at low flow rates in comparisons with isoflurane. Because of its low blood: gas solubility, sevoflurane is rapidly taken up and eliminated. The alveolar ‘wash-in’ rate in children is about 50% higher with sevoflurane than with halothane when either is given with N2O. Like other fluorinated ethers, sevoflurane undergoes dose-independent hepatic biotransformation by cytochrome P450 (CYP) 2E1, principally to inorganic fluoride ions (F−) and hexafluoroisopropanol (HEIP). Up to 50% of plasma F− is cleared via uptake into bone. Sevoflurane undergoes negligible renal defluorination compared with methoxyflurane. Sevoflurane is eliminated more rapidly than halothane in children; the alveolar ‘washout’ rate is halved. Sevoflurane reduces time to induction and emergence compared with halothane in children undergoing ambulatory and nonambulatory surgery, although the clinical importance of the difference in time to induction has been questioned. Time to induction is reduced with increasing sevoflurane concentration, use of high concentration versus incremental concentrations and the addition of N2O. The rapid emergence from sevoflurane anaesthesia is desirable but appears to result in earlier and more intense discomfort or pain (as measured by objective pain/discomfort scores and use of postoperative analgesia). Time to discharge from the recovery area is generally at least as fast, and patient acceptability of the anaesthetic is at least as good, with sevoflurane as with halothane. Data are insufficient to allow any firm conclusions regarding the relative anaesthetic efficacy of sevoflurane compared with desflurane or propofol. Several clinical studies demonstrate that children can successfully undergo tracheal intubation without a muscle relaxant or LMA insertion while receiving sevoflurane induction anaesthesia. Although sevoflurane has been the subject of a number of theoretical cost analyses, detailed data are scarce and well designed formal cost effectiveness comparisons with other agents are not available. The incidence of adverse events occurring most often during induction and emergence — coughing, laryngospasm, breath-holding and agitation/excitement — is generally similar for sevoflurane and halothane. Available evidence does not consistently show differences between the 2 drugs in their propensity to cause postoperative excitement. EEG patterns for the 2 drugs have been shown to be dissimilar, but seizure-like movement seen during sevoflurane anaesthesia has not been causally related to the drug. Sevoflurane increases heart rate to a greater extent than halothane during induction but causes fewer instances of arrhythmias and bradycardia during anaesthesia. Sevoflurane may cause postoperative nausea and vomiting (PONV) less often than halothane; individual trials show a similar incidence of PONV for sevoflurane compared with desflurane, isoflurane and propofol. Despite elevated plasma F− levels, sevoflurane and other inhalation anaesthetic agents are not associated with nephrotoxicity. Numerous trials in children demonstrate that plasma F− levels remain below the theoretical ‘toxic threshold’ of 50 μmol/L (for methoxyflurane) during sevoflurane anaesthesia lasting up to 9 MAC · h, with no renal impairment evident. There have been no reports of PIFE-associated nephrotoxicity in children or adults anaesthetised with sevoflurane. The potential for hepatic injury with sevoflurane is expected to be negligible; sevoflurane does not generate antigenic trifluoroacetyl proteins and its organic metabolite HFIP has a low binding affinity for hepatic tissue and is rapidly glucoronidated and excreted. Increases in levels of serum glutathione S-transferase α seen in one series of children anaesthetised with sevoflurane or halothane were not evident in another group given sevoflurane. Like other inhalation anaesthetic agents, sevoflurane has the potential to cause malignant hyperthermia; only 2 such cases have been reported in children to date. Sevoflurane prolongs the duration of neuromuscular blockade induced by non-depolarising muscle relaxants such as vecuronium to a greater extent than halothane or isoflurane. Dosages of neuromuscular blockers should be reduced when sevoflurane anaesthesia is used. Agents such as isoniazid and alcohol that induce cytochrome P450 2E1 may increase sevoflurane metabolism. Whether sevoflurane may displace highly bound drugs such as phenytoin is unknown, but this interaction has occurred with other volatile fluorinated anaesthetics. Sevoflurane is synergistic with lidocaine (lignocaine) and procainamide in prolonging ventricular activation time. Sevoflurane is administered by inhalation with a vaporiser specifically calibrated for the agent. Delivery should be individualised according to the patient’s response. Sevoflurane concentrations needed to induce anaesthesia are greater in children than in adults. Inspired sevoflurane concentrations of 7 or 8% have been used successfully to induce anaesthesia in many studies in children. Sevoflurane is most often administered with N2O plus O2. Sevoflurane concentrations of 0.5 to 3% are sufficient to maintain anaesthesia during surgery. There are no flow rate restrictions in most countries where sevoflurane is approved. Sevoflurane is contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia and should be used with caution in patients with renal insufficiency. Levels of the organic metabolite PIFE are higher when barium hydroxide lime rather than soda lime is used as a CO2 absorbent.

This publication has 100 references indexed in Scilit: